Better-than-expected performances from GSK plc’s vaccines, HIV and respiratory divisions helped get the firm off to a strong start in the first quarter, as it awaits approval of the first preventative vaccine for respiratory syncytial virus (RSV) and contemplates more bolt-on acquisitions and deals.
Having outperformed in 2022, the strong momentum for the UK major continued in the first quarter, with total sales of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?